Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J.
Am J Psychiatry. 2023 Sep 1;180(9):668-675. doi: 10.1176/appi.ajp.20220785. Epub 2023 Jul 26.
Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.
Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N.
Lancet. 2019 Feb 23;393(10173):768-777. doi: 10.1016/S0140-6736(18)31793-8. Epub 2019 Jan 31.
The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders.
Maier W, Buller R, Philipp M, Heuser I.
J Affect Disord. 1988 Jan-Feb;14(1):61-8. doi: 10.1016/0165-0327(88)90072-9.
Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study.
Rudzki L, Ostrowska L, Pawlak D, Małus A, Pawlak K, Waszkiewicz N, Szulc A.
Psychoneuroendocrinology. 2019 Feb;100:213-222. doi: 10.1016/j.psyneuen.2018.10.010. Epub 2018 Oct 16.
Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study.
Langade D, Thakare V, Kanchi S, Kelgane S.
J Ethnopharmacol. 2021 Jan 10;264:113276. doi: 10.1016/j.jep.2020.113276. Epub 2020 Aug 17.
Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial.
Croarkin PE, Elmaadawi AZ, Aaronson ST, Schrodt GR Jr, Holbert RC, Verdoliva S, Heart KL, Demitrack MA, Strawn JR.
Neuropsychopharmacology. 2021 Jan;46(2):462-469. doi: 10.1038/s41386-020-00829-y. Epub 2020 Sep 12.
The Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment-Resistant Bipolar Depression.
Zengin G, Topak OZ, Atesci O, Culha Atesci F.
Psychiatr Danub. 2022 Summer;34(2):236-244. doi: 10.24869/psyd.2022.236.
Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial.
Mao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, Amsterdam JD.
Phytomedicine. 2015 Mar 15;22(3):394-9. doi: 10.1016/j.phymed.2015.01.010. Epub 2015 Feb 23.
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
Adair M, Christensen MC, Florea I, Loft H, Fagiolini A.
J Affect Disord. 2023 May 1;328:345-354. doi: 10.1016/j.jad.2023.01.074. Epub 2023 Jan 26.
Exercise and pharmacotherapy in the treatment of major depressive disorder.
Blumenthal JA, Babyak MA, Doraiswamy PM, Watkins L, Hoffman BM, Barbour KA, Herman S, Craighead WE, Brosse AL, Waugh R, Hinderliter A, Sherwood A.
Psychosom Med. 2007 Sep-Oct;69(7):587-96. doi: 10.1097/PSY.0b013e318148c19a. Epub 2007 Sep 10.
